Alterity Therapeutics Limited Logo

Alterity Therapeutics Limited

PRNAF

(1.0)
Stock Price

0,00 USD

-146.44% ROA

-137.73% ROE

-1.2x PER

Market Cap.

28.449.815,87 USD

1.15% DER

0% Yield

-448.63% NPM

Alterity Therapeutics Limited Stock Analysis

Alterity Therapeutics Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Alterity Therapeutics Limited Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

3 ROE

The stock's ROE indicates a negative return (0%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (0%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

6 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Alterity Therapeutics Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Alterity Therapeutics Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

Alterity Therapeutics Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Alterity Therapeutics Limited Revenue
Year Revenue Growth
1998 0
1999 0 0%
2000 78.758 100%
2001 516.182 84.74%
2002 794.393 35.02%
2003 1.811.086 56.14%
2004 2.307.120 21.5%
2005 2.642.335 12.69%
2006 762.486 -246.54%
2007 507.044 -50.38%
2008 491.997 -3.06%
2009 428.193 -14.9%
2010 215.008 -99.15%
2011 156.135 -37.71%
2012 186.664 16.36%
2013 150.867 -23.73%
2014 363.775 58.53%
2015 176.842 -105.71%
2016 142.657 -23.96%
2017 132.396 -7.75%
2018 201.174 34.19%
2019 108.538 -85.35%
2020 0 0%
2021 4.339.599 100%
2022 5.123.525 15.3%
2023 3.916.333 -30.82%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Alterity Therapeutics Limited Research and Development Expenses
Year Research and Development Expenses Growth
1998 0
1999 0 0%
2000 421.933 100%
2001 2.376.404 82.24%
2002 2.481.267 4.23%
2003 1.855.770 -33.71%
2004 5.200.780 64.32%
2005 7.656.367 32.07%
2006 7.617.672 -0.51%
2007 4.491.259 -69.61%
2008 5.769.530 22.16%
2009 2.215.358 -160.43%
2010 87.992 -2417.68%
2011 2.329.491 96.22%
2012 4.228.719 44.91%
2013 7.946.005 46.78%
2014 14.908.098 46.7%
2015 12.298.167 -21.22%
2016 9.585.371 -28.3%
2017 5.700.339 -68.15%
2018 6.698.016 14.9%
2019 12.983.185 48.41%
2020 10.098.049 -28.57%
2021 12.283.848 17.79%
2022 14.745.776 16.7%
2023 13.198.583 -11.72%
2024 49.132.052 73.14%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Alterity Therapeutics Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 4.305.048 100%
2007 6.732.239 36.05%
2008 0 0%
2009 5.265.587 100%
2010 3.921.780 -34.27%
2011 3.565.228 -10%
2012 506.927 -603.3%
2013 3.115.733 83.73%
2014 3.090.344 -0.82%
2015 4.060.235 23.89%
2016 3.587.742 -13.17%
2017 3.947.302 9.11%
2018 4.319.259 8.61%
2019 4.278.656 -0.95%
2020 3.333.712 -28.35%
2021 6.862.473 51.42%
2022 5.459.701 -25.69%
2023 4.987.937 -9.46%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Alterity Therapeutics Limited EBITDA
Year EBITDA Growth
1998 -690
1999 -80.000 99.14%
2000 -343.175 76.69%
2001 -1.860.222 81.55%
2002 -3.378.499 44.94%
2003 -1.831.265 -84.49%
2004 -6.766.154 72.93%
2005 1.825.733 470.6%
2006 -10.981.970 116.62%
2007 -10.782.296 -1.85%
2008 -11.852.437 9.03%
2009 -9.020.013 -31.4%
2010 -4.859.474 -85.62%
2011 -6.241.682 22.14%
2012 -7.718.895 19.14%
2013 -7.887.197 2.13%
2014 -12.530.284 37.05%
2015 -10.574.931 -18.49%
2016 -9.179.282 -15.2%
2017 -5.958.430 -54.06%
2018 -10.603.413 43.81%
2019 -12.684.165 16.4%
2020 -10.301.594 -23.13%
2021 -14.432.012 28.62%
2022 -17.805.538 18.95%
2023 -18.420.810 3.34%
2024 -60.112.520 69.36%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Alterity Therapeutics Limited Gross Profit
Year Gross Profit Growth
1998 0
1999 0 0%
2000 78.758 100%
2001 516.182 84.74%
2002 794.393 35.02%
2003 1.811.086 56.14%
2004 2.307.120 21.5%
2005 2.642.335 12.69%
2006 762.486 -246.54%
2007 507.044 -50.38%
2008 491.997 -3.06%
2009 428.193 -14.9%
2010 215.008 -99.15%
2011 -243.102 188.44%
2012 186.664 230.24%
2013 4.488.526 95.84%
2014 8.209.171 45.32%
2015 -80.457 10303.18%
2016 119.847 167.13%
2017 111.068 -7.9%
2018 179.375 38.08%
2019 78.842 -127.51%
2020 -112.427 170.13%
2021 4.264.230 102.64%
2022 5.069.311 15.88%
2023 3.814.070 -32.91%
2024 -294.448 1395.33%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Alterity Therapeutics Limited Net Profit
Year Net Profit Growth
1998 -690
1999 -80.000 99.14%
2000 -1.326.288 93.97%
2001 -4.138.979 67.96%
2002 -5.451.373 24.07%
2003 -4.571.229 -19.25%
2004 -9.825.533 53.48%
2005 -24.907.010 60.55%
2006 -11.726.433 -112.4%
2007 -11.140.002 -5.26%
2008 -13.589.797 18.03%
2009 -7.522.789 -80.65%
2010 -4.906.922 -53.31%
2011 -6.431.185 23.7%
2012 -5.239.469 -22.74%
2013 -7.787.242 32.72%
2014 -13.329.239 41.58%
2015 -5.885.069 -126.49%
2016 -7.729.551 23.86%
2017 -7.542.076 -2.49%
2018 -8.265.737 8.75%
2019 -12.337.830 33%
2020 -10.059.684 -22.65%
2021 -15.309.353 34.29%
2022 -12.847.061 -19.17%
2023 -13.806.515 6.95%
2024 -50.465.124 72.64%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Alterity Therapeutics Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Alterity Therapeutics Limited Free Cashflow
Year Free Cashflow Growth
2002 -3.852.260
2003 -3.667.624 -5.03%
2004 -5.448.466 32.69%
2005 -11.422.690 52.3%
2006 -11.713.956 2.49%
2007 -9.202.394 -27.29%
2008 -9.458.263 2.71%
2009 -7.030.366 -34.53%
2010 -4.731.606 -48.58%
2011 -4.572.106 -3.49%
2012 -6.872.669 33.47%
2013 -7.973.254 13.8%
2014 -13.812.021 42.27%
2015 -10.899.831 -26.72%
2016 -7.420.833 -46.88%
2017 -5.892.998 -25.93%
2018 -6.307.593 6.57%
2019 -13.961.840 54.82%
2020 -9.447.866 -47.78%
2021 -17.333.069 45.49%
2022 -12.426.274 -39.49%
2023 -5.000 -248425.48%
2023 -20.043.148 99.98%
2024 -8.110.606 -147.12%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Alterity Therapeutics Limited Operating Cashflow
Year Operating Cashflow Growth
2002 -3.767.983
2003 -3.579.956 -5.25%
2004 -5.314.920 32.64%
2005 -11.372.429 53.26%
2006 -11.658.297 2.45%
2007 -9.197.836 -26.75%
2008 -9.411.557 2.27%
2009 -6.994.174 -34.56%
2010 -4.708.939 -48.53%
2011 -4.558.415 -3.3%
2012 -6.845.906 33.41%
2013 -7.951.254 13.9%
2014 -13.788.974 42.34%
2015 -10.871.074 -26.84%
2016 -7.418.526 -46.54%
2017 -5.865.080 -26.49%
2018 -6.245.188 6.09%
2019 -13.954.818 55.25%
2020 -9.431.122 -47.97%
2021 -17.330.069 45.58%
2022 -12.337.274 -40.47%
2023 0 0%
2023 -20.035.837 100%
2024 -8.110.884 -147.02%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Alterity Therapeutics Limited Capital Expenditure
Year Capital Expenditure Growth
2002 84.277
2003 87.668 3.87%
2004 133.545 34.35%
2005 50.261 -165.7%
2006 55.659 9.7%
2007 4.558 -1121.13%
2008 46.706 90.24%
2009 36.192 -29.05%
2010 22.667 -59.67%
2011 13.691 -65.56%
2012 26.763 48.84%
2013 22.000 -21.65%
2014 23.047 4.54%
2015 28.757 19.86%
2016 2.307 -1146.51%
2017 27.918 91.74%
2018 62.405 55.26%
2019 7.022 -788.71%
2020 16.744 58.06%
2021 3.000 -458.13%
2022 89.000 96.63%
2023 5.000 -1680%
2023 7.311 31.61%
2024 -278 2729.86%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Alterity Therapeutics Limited Equity
Year Equity Growth
1998 -670
1999 -80.670 99.17%
2000 20.729.307 100.39%
2001 21.392.877 3.1%
2002 16.677.878 -28.27%
2003 15.776.735 -5.71%
2004 38.467.340 58.99%
2005 19.514.582 -97.12%
2006 8.734.655 -123.42%
2007 5.611.027 -55.67%
2008 9.887.513 43.25%
2009 3.749.816 -163.68%
2010 5.229.316 28.29%
2011 6.931.202 24.55%
2012 5.623.447 -23.26%
2013 13.974.713 59.76%
2014 37.686.287 62.92%
2015 39.113.264 3.65%
2016 31.367.213 -24.69%
2017 23.690.034 -32.41%
2018 16.081.157 -47.32%
2019 16.554.773 2.86%
2020 10.547.930 -56.95%
2021 30.470.460 65.38%
2022 35.468.591 14.09%
2022 28.103.747 -26.21%
2023 22.812.909 -23.19%
2024 13.798.057 -65.33%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Alterity Therapeutics Limited Assets
Year Assets Growth
1998 199.285
1999 1.836.945 89.15%
2000 20.876.444 91.2%
2001 22.287.460 6.33%
2002 17.590.697 -26.7%
2003 16.341.277 -7.65%
2004 41.163.692 60.3%
2005 22.198.618 -85.43%
2006 10.427.480 -112.89%
2007 7.720.578 -35.06%
2008 11.723.433 34.14%
2009 4.597.250 -155.01%
2010 6.801.417 32.41%
2011 9.010.952 24.52%
2012 7.341.868 -22.73%
2013 17.073.821 57%
2014 41.640.855 59%
2015 41.834.382 0.46%
2016 33.725.020 -24.05%
2017 25.280.946 -33.4%
2018 18.726.013 -35%
2019 19.909.918 5.95%
2020 13.304.834 -49.64%
2021 33.585.754 60.39%
2022 41.362.611 18.8%
2022 33.382.930 -23.9%
2023 27.317.636 -22.2%
2024 19.223.743 -42.1%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Alterity Therapeutics Limited Liabilities
Year Liabilities Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 912.819 100%
2003 564.541 -61.69%
2004 2.696.351 79.06%
2005 2.684.035 -0.46%
2006 1.692.824 -58.55%
2007 2.109.551 19.75%
2008 1.835.920 -14.9%
2009 847.434 -116.64%
2010 1.572.101 46.1%
2011 2.079.750 24.41%
2012 1.718.421 -21.03%
2013 3.099.108 44.55%
2014 3.954.568 21.63%
2015 2.721.118 -45.33%
2016 2.357.807 -15.41%
2017 1.590.912 -48.2%
2018 2.644.856 39.85%
2019 3.355.145 21.17%
2020 2.756.904 -21.7%
2021 3.115.294 11.5%
2022 5.894.020 47.14%
2022 5.279.183 -11.65%
2023 4.504.727 -17.19%
2024 5.425.686 16.97%

Alterity Therapeutics Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0
Price to Earning Ratio
-1.2x
Price To Sales Ratio
10.67x
POCF Ratio
-2.8
PFCF Ratio
-2.36
Price to Book Ratio
2.44
EV to Sales
5.99
EV Over EBITDA
-0.46
EV to Operating CashFlow
-1.32
EV to FreeCashFlow
-1.32
Earnings Yield
-0.83
FreeCashFlow Yield
-0.42
Market Cap
0,03 Bil.
Enterprise Value
0,02 Bil.
Graham Number
0.01
Graham NetNet
0

Income Statement Metrics

Net Income per Share
-0
Income Quality
0.54
ROE
-1.57
Return On Assets
-1.3
Return On Capital Employed
-2.27
Net Income per EBT
0.82
EBT Per Ebit
0.97
Ebit per Revenue
-5.66
Effective Tax Rate
0.18

Margins

Sales, General, & Administrative to Revenue
1.19
Research & Developement to Revenue
10.22
Stock Based Compensation to Revenue
0.12
Gross Profit Margin
0.96
Operating Profit Margin
-5.66
Pretax Profit Margin
-5.48
Net Profit Margin
-4.49

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
-0
Capex to Revenue
0
Capex to Depreciation
0.05
Return on Invested Capital
-2.08
Return on Tangible Assets
-1.46
Days Sales Outstanding
553.35
Days Payables Outstanding
854.34
Days of Inventory on Hand
0
Receivables Turnover
0.66
Payables Turnover
0.43
Inventory Turnover
248280
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
0.01
Debt to Assets
0.01
Net Debt to EBITDA
0.36
Current Ratio
3.54
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
13849971
Working Capital
0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,01 Bil.
Average Payables
0,00 Bil.
Average Inventory
0.5
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Alterity Therapeutics Limited Dividends
Year Dividends Growth

Alterity Therapeutics Limited Profile

About Alterity Therapeutics Limited

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

CEO
Dr. David A. Stamler M.D.
Employee
10
Address
460 Bourke Street
Melbourne, 3000

Alterity Therapeutics Limited Executives & BODs

Alterity Therapeutics Limited Executives & BODs
# Name Age
1 Mr. Geoffrey Paul Kempler B.Sc.
Co-Founder & Non-Executive Chairman
70
2 Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A.
Chief Financial Officer & Company Secretary
70
3 Dr. Rudolph Emile Tanzi Ph.D.
Chief Scientific Advisor and Member of Research & Development Advisory Board
70
4 Dr. Steven D. Targum M.D.
Chief Medical Advisor
70
5 Dr. Robert Cherny
Head of Research
70
6 Dr. David A. Stamler M.D.
Chief Executive Officer
70

Alterity Therapeutics Limited Competitors